• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Homology Medicines Inc.

    3/29/24 4:30:59 PM ET
    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FIXX alert in real time by email
    SC 13G 1 d788523dsc13g.htm SC 13G SC 13G

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.  )*

     

     

    Q32 Bio Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    746964105

    (CUSIP Number)

    March 25, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 746964105    Schedule 13G    Page 1 of 16

     

     1   

    Names of Reporting Persons

     

    The Carlyle Group Inc.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    CO


    CUSIP No. 746964105    Schedule 13G    Page 2 of 16

     

     1   

    Names of Reporting Persons

     

    Carlyle Holdings I GP Inc.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    CO


    CUSIP No. 746964105    Schedule 13G    Page 3 of 16

     

     1   

    Names of Reporting Persons

     

    Carlyle Holdings I GP Sub L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 746964105    Schedule 13G    Page 4 of 16

     

     1   

    Names of Reporting Persons

     

    Carlyle Holdings I L.P.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. 746964105    Schedule 13G    Page 5 of 16

     

     1   

    Names of Reporting Persons

     

    CG Subsidiary Holdings L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 746964105    Schedule 13G    Page 6 of 16

     

     1   

    Names of Reporting Persons

     

    TC Group, L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 746964105    Schedule 13G    Page 7 of 16

     

     1   

    Names of Reporting Persons

     

    Carlyle Investment Management L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 746964105    Schedule 13G    Page 8 of 16

     

     1   

    Names of Reporting Persons

     

    Carlyle Genesis UK LLC

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 746964105    Schedule 13G    Page 9 of 16

     

     1   

    Names of Reporting Persons

     

    Abingworth LLP

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    England and Wales

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. 746964105    Schedule 13G    Page 10 of 16

     

     1   

    Names of Reporting Persons

     

    Abingworth Bioventures VII LP

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    England and Wales

    Number of Shares Beneficially Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,102,741

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,102,741

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,102,741

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    9.2%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. 746964105    Schedule 13G    Page 11 of 16

     

    ITEM 1. (a)

    Name of Issuer:

    Q32 Bio Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    830 Winter Street, Waltham, MA 02451

     

    ITEM 2. (a)

    Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    The Carlyle Group Inc.

    Carlyle Holdings I GP Inc.

    Carlyle Holdings I GP Sub L.L.C.

    Carlyle Holdings I L.P.

    CG Subsidiary Holdings L.L.C.

    TC Group, L.L.C.

    Carlyle Investment Management L.L.C.

    Carlyle Genesis UK LLC

    Abingworth LLP

    Abingworth Bioventures VII LP

     

      (b)

    Address or Principal Business Office:

    The principal business address of each of Abingworth LLP and Abingworth Bioventures VII LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.

     

      (c)

    Citizenship of each Reporting Person is:

    Each of Abingworth LLP and Abingworth Bioventures VII LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

     

      (d)

    Title of Class of Securities:

    Common Stock, par value $0.0001 per share (“Common Stock”).


    CUSIP No. 746964105    Schedule 13G    Page 12 of 16

     

      (e)

    CUSIP Number:

    746964105

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of March 25, 2024, based upon 11,929,528 shares of Common Stock outstanding, as disclosed in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 27, 2024.

     

    Reporting Person

       Amount
    beneficially 
    owned
         Percent
    of class
        Sole
    power to
    vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole
    power to
    dispose or
    to direct
    the
    disposition
         Shared
    power to
    dispose or
    to direct
    the
    disposition
     

    The Carlyle Group Inc.

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Carlyle Holdings I GP Inc.

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Carlyle Holdings I GP Sub L.L.C.

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Carlyle Holdings I L.P.

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    CG Subsidiary Holdings L.L.C.

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    TC Group, L.L.C.

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Carlyle Investment Management L.L.C.

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Carlyle Genesis UK LLC

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Abingworth LLP

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Abingworth Bioventures VII LP

         1,102,741        9.2 %      0        1,102,741        0        1,102,741  

    Abingworth Bioventures VII LP is the record holder of the shares of Common Stock reported herein.

    The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by them. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.


    CUSIP No. 746964105    Schedule 13G    Page 13 of 16

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 746964105    Schedule 13G    Page 14 of 16

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: March 29, 2024

     

    The Carlyle Group Inc.
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Chief Financial Officer
    Carlyle Holdings I GP Inc.
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Managing Director and Chief Financial Officer
    Carlyle Holdings I GP Sub L.L.C.
    By: Carlyle Holdings I GP Inc., its sole member
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Managing Director and Chief Financial Officer
    Carlyle Holdings I L.P.
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Managing Director
    CG Subsidiary Holdings L.L.C.
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Managing Director
    TC Group, L.L.C.
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Managing Director


    CUSIP No. 746964105    Schedule 13G    Page 15 of 16

     

    Carlyle Investment Management L.L.C.
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Chief Financial Officer
    Carlyle Genesis UK LLC
    By: Carlyle Investment Management L.L.C., its sole
    member  
    By:  

    /s/ Anne Frederick, attorney-in-fact

    Name:   John C. Redett
    Title:   Chief Financial Officer
    Abingworth LLP
    By:  

    /s/ John Heard

    Name:   John Heard
    Title:   Authorized Signatory
    Abingworth Bioventures VII LP
    By:  

    /s/ John Heard

    Name:   John Heard
    Title:   Authorized Signatory


    CUSIP No. 746964105    Schedule 13G    Page 16 of 16

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    24    Power of Attorney.
    99    Joint Filing Agreement.

     

    Get the next $FIXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FIXX

    DatePrice TargetRatingAnalyst
    7/28/2023$9.00 → $1.50Outperform → Neutral
    Robert W. Baird
    2/28/2022$30.00 → $20.00Buy
    HC Wainwright & Co.
    2/22/2022$25.00 → $9.00Buy
    B of A Securities
    2/22/2022$35.00 → $29.00Neutral
    BTIG Research
    2/22/2022Outperform → Sector Perform
    RBC Capital Mkts
    2/22/2022$25.00 → $15.00Buy
    Chardan Capital
    2/22/2022$35.00 → $29.00Buy
    BTIG
    2/22/2022$30.00 → $4.00Outperform → Sector Perform
    RBC Capital
    More analyst ratings

    $FIXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

      BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the "Gene Editing Corporate Panel" during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology's website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients

      3/2/23 7:30:54 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines to Participate at Upcoming Conferences

      BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT"Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic" panel featuring Dr. Seymour on October 11 at 4:00 p.m. PT"New Business Models for Manufacturing Investment" panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at 3:15 p.m. PT

      10/6/22 8:30:27 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

      SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa

      9/27/22 8:15:00 AM ET
      $AKUS
      $CINC
      $FIXX
      $IONS
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Homology Medicines Inc.

      424B3 - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:26:07 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Homology Medicines Inc.

      10-Q - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:18:33 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:06:23 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Homology Medicines downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously

      7/28/23 7:17:02 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Homology Medicines with a new price target

      HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously

      2/28/22 7:12:58 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B of A Securities reiterated coverage on Homology Medicines with a new price target

      B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously

      2/22/22 10:12:45 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Alloway Paul sold $6,488 worth of shares (268 units at $24.21), decreasing direct ownership by 9% to 2,596 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:03:07 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Michaud Charles Jr sold $1,815 worth of shares (75 units at $24.20), decreasing direct ownership by 7% to 927 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:00:03 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tzianabos Arthur

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      3/27/24 5:43:06 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Leadership Updates

    Live Leadership Updates

    See more
    • Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

      - ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr

      8/5/21 8:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Homology Medicines Inc. (Amendment)

      SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

      5/13/24 5:34:55 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/4/24 8:33:33 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/1/24 9:52:41 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Financials

    Live finance-specific insights

    See more
    • Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner

      Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business  Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts t

      1/28/22 2:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care